公开(公告)号：US20060217429A1

公开(公告)日：2006-09-28

申请号：US11441648

申请日：2006-05-25

Applicant: Hugh Montgomery ,  John Martin ,  Jorge Erusalimsky

Inventor： Hugh Montgomery ,  John Martin ,  Jorge Erusalimsky

IPC: A61K31/4184 ,  A61K31/401

CPC classification number: A61K45/06 ,  A61K31/00 ,  A61K31/22 ,  A61K31/223 ,  A61K31/40 ,  A61K31/401 ,  A61K31/403 ,  A61K31/405 ,  A61K31/407 ,  A61K31/41 ,  A61K31/415 ,  A61K31/417 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K31/554 ,  A61K31/66 ,  A61K31/662 ,  C08G61/08

Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

公开(公告)号：US20050192327A1

公开(公告)日：2005-09-01

申请号：US11119181

申请日：2005-04-29

Applicant: Hugh Montgomery ,  John Martin ,  Jorge Erusalimsky

Inventor： Hugh Montgomery ,  John Martin ,  Jorge Erusalimsky

IPC: A61K45/00 ,  A61K31/00 ,  A61K31/22 ,  A61K31/223 ,  A61K31/40 ,  A61K31/401 ,  A61K31/403 ,  A61K31/405 ,  A61K31/407 ,  A61K31/41 ,  A61K31/415 ,  A61K31/417 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K31/554 ,  A61K31/66 ,  A61K31/662 ,  A61K38/00 ,  A61P3/00 ,  A61P7/00 ,  A61P9/10 ,  A61P25/00 ,  A61P37/04 ,  A61P43/00 ,  C08G61/08 ,  C12Q1/00

CPC classification number: A61K45/06 ,  A61K31/00 ,  A61K31/22 ,  A61K31/223 ,  A61K31/40 ,  A61K31/401 ,  A61K31/403 ,  A61K31/405 ,  A61K31/407 ,  A61K31/41 ,  A61K31/415 ,  A61K31/417 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K31/554 ,  A61K31/66 ,  A61K31/662 ,  C08G61/08

Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.